|
![]() |
![]() ![]() |
![]() |
|
||
![]() |
![]() |
Re: Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).This is the original reason the anti-miR-17 program was started. It was in the AZ oncology collaboration.It is interesting that it ended up making it to the clinic in kidney disease.
|
![]() ![]() ![]() ![]() |
return to message board, top of board |